Rhumbline Advisers Entrada Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 39,095 shares of TRDA stock, worth $201,730. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,095
Previous 36,113
8.26%
Holding current value
$201,730
Previous $326,000
19.63%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TRDA
# of Institutions
106Shares Held
28.6MCall Options Held
15.7KPut Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$25.1 Million0.33% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$22.6 Million67.92% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.31MShares$22.2 Million19.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.57MShares$13.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$8.74 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $162M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...